NEUROGENE INC (NGNE)
Health Care · Gene therapy / genetic medicines for neurological diseases · NASDAQ
Neurogene is a clinical-stage gene therapy company utilizing proprietary transgene regulation technology to develop treatments for rare, devastating neurological diseases.
What NEUROGENE INC does
Neurogene is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. The company leverages its proprietary EXACT™ (Expression Attenuation via Construct Tuning) transgene regulation technology, which uses microRNA-based genetic circuits to deliver therapeutic levels of transgene to key brain areas. Its lead program, NGN-401, is in registrational trial (Embolden) for Rett syndrome using AAV delivery via intracerebroventricular administration, with an in-house cGMP manufacturing facility in Houston, Texas.
Themes: Gene therapy / genetic medicines, Rare neurological diseases, Rett syndrome, AAV therapeutics, CNS / neurological drug development
Fundamentals
- Price$38.63 as of 2026-08-21 close
- Market cap$773M as of 2026-08-21
- 1-year return+95.6% 2025-08-21 close $19.75 → 2026-08-21 close $38.63
- P/En/a negative earnings
- Net margin-8123.7% as of 2026-08-24
- ROE-25.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.68 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How NGNE compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NEUROGENE INC looks technically
NEUROGENE INC (NGNE) is trading 51.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 80 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 51.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +51.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $34.69 | $34.69 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $25.58 | $25.58 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 30.57. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 80 trading days ago — a "golden cross", a bullish long-term signal | 80 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($30.57 to $40.16) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 84.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $43.66 | $43.66 |
|---|---|---|
| From the 52-week high | it is 11.5% below its 52-week high (its highest price of the past year) | -11.5% |
| Above the 52-week low | it is 142.5% above its 52-week low (its lowest price of the past year) | +142.5% |
| Below the 52-week high | it is 11.5% below its highest point of the past year | 11.5% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 31 trading days ago | 31 sessions |
| All-time high | its highest closing price on record is $1115.00 (set on 2015-08-10) | $1115.00 |
| Given back of the 52-week move | over the past year its closes ranged ($16.37 to $42.84), and it has given back roughly a quarter of its rise from last year’s low — 16% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.63 to $26.48. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 15.9% |
| From the all-time high | it is 96.5% below its all-time high | -96.5% |
| Nearest price level | it is trading 1.2% above a support level at $38.16 — a price it turned at twice since 2024-08-30, most recently on 2024-10-02. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.2% |
| All-time low | its lowest closing price on record is $6.88 (set on 2025-04-08) | $6.88 |
| Above the all-time low | it is 461.9% above its all-time low | +461.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.40 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.40 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $32.01 and $39.20 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $32.01 – $35.60 – $39.20 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 5.5 daily ranges above its 200-day average price (51.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.73× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 3.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 35.67 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.3% |
| Gap filled | a 2.2% gap down opened on 2026-08-20 has been "filled" today — price traded back through the level the gap left behind, and it took 1 session to close | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.0 percentage points (the stock gained 5.3% while the market gained 2.3%) | +3.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 36.8 percentage points (the stock gained 39.9% while the market gained 3.1%) | +36.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 107.9 percentage points (the stock gained 119.0% while the market gained 11.1%) | +107.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 75.1 percentage points (the stock gained 95.6% while the market gained 20.5%) | +75.1% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.6% of the share price. | +7.1% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 39% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $27.89 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +38.5% |
|---|
Price levels it has turned at before
NGNE last closed at $38.63 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $38.16 | Support | 1.2% below the last close | turned there twice · 2024-08-30 to 2024-10-02 |
| $32.00 | Support | 17.2% below the last close | turned there three times · 2024-09-04 to 2026-07-31 |
| $28.93 | Support | 25.1% below the last close | turned there twice · 2026-04-17 to 2026-06-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $30.57.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $49.32 and $60.91 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $30.57.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$80.43 range $46.00 – $166.00; median $65.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NGNE
- Consensus EPS estimate-$1.37 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: NGN-401 is in early registrational trial for Rett syndrome with uncertain regulatory approval pathway; failure to meet efficacy endpoints would block commercialization","Capital requirements: Company is pre-commercial with accumulated deficit of $352.6 million and net losses of $90.4 million in 2025; requires additional financing to fund ongoing clinical development and manufacturing scale-up","Manufacturing and supply chain: Reliance on in-house cGMP facility and AAV manufacturing capacity to support clinical trials and future commercial scale-up; any manufacturing disruption could delay programs"]
What changed in the latest 10-Q
AI-assisted comparison of NGNE's 10-Q filed 2026-05-12 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 'Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026' (2026-05-12 filing)
- Newer filing states 'Approximately 90% of participants have been dosed in Embolden, and we are on track to complete dosing in the second quarter of 2026'
- Newer filing describes NGN-401 as 'purposefully designed to utilize the EXACT platform and adeno-associated virus (AAV) delivery via intracerebroventricular (ICV) administration, and to deliver the full-length MECP2 gene which preserves the complete set of endogenous regulatory elements to restore functional MeCP2 protein'
- Newer filing states 'Clinical grade NGN-401 manufactured at our fully operational current good manufacturing practices (cGMP) facility in Houston, Texas'
- Newer filing includes statement 'We believe that our in-house manufacturing capabilities better enable control of product quality and development timelines, strategic pipeline and financial flexibility, and clinical-to-commercial continuity'
- Newer filing specifies 'The trial is assessing the safety, tolerability, and efficacy of NGN-401 at a dose of 1E15 vg in eight participants in an ages 4-10 years cohort and two participants in an ages 11 years and older cohort'
- Newer filing states 'As of October 30, 2025, four out of five participants with at least 12 months of follow-up met the responder definition of the primary endpoint planned for assessment at Month 12 in the Embolden trial'
- Newer filing reports 'no cases of hemophagocytic lymphohistiocytosis (HLH) in any participant at this dose'
- Removed:
- Older filing references 'Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 24, 2025' (2025-11-13 filing)
- Older filing states 'The first participant was dosed during the fourth quarter of 2025'
- Older filing references 'Part II, Section 1A' instead of 'Part II, Item 1A'
- Older filing states Embolden trial is 'evaluating the 1E15 vg dose of NGN-401 in 20 females with Rett syndrome'
- Older filing describes approach as 'By harnessing our proprietary transgene regulation technology... we are developing a differentiated product portfolio' and details the EXACT approach separately
- Older filing states 'Clinical grade NGN-401 is manufactured at our manufacturing facility' without specific location or cGMP designation
- Older filing includes detailed description of primary endpoint definition and responder criteria with 35% response rate threshold (7 out of 20 patients)
- Older filing states 'The Embolden trial is expected to enroll across 13 sites and completion of enrollment in the trial is expected in three to six months'
- Older filing includes 'We previously gained alignment with the FDA on our potency assay strategy and chemistry, manufacturing and control (CMC) scale-up planning for the program'
- Older filing includes section on 'baseline demographics of the eight participants in the pediatric cohort'
- Reworded:
- Older text 'We are building a robust and differentiated product portfolio' changed to newer text 'One approach we are taking harnesses our proprietary transgene regulation technology'
- Older text describing the overview of EXACT approach integrated into narrative changed to newer text with separate, focused language on NGN-401 design
- Older text 'Our first clinical-stage program to utilize the EXACT platform is NGN-401, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death' changed to newer text 'Our first clinical-stage program, NGN-401, is in development for the treatment of Rett syndrome, a severe and progressive neurodevelopmental disease with substantial neurological and physical impairments and significant unmet need'
- Older text 'developmental milestones/skills' changed to newer text 'developmental milestones' (terminology simplified)
- Notes:
- Older filing text appears truncated at end ('All developmental mil'), making complete comparison difficult for final sections
- Progress updates reflect natural timeline progression between filings (Q3 2025 filing vs Q1 2026 filing)
Risk Factors
- Added:
- Added bullet point in Summary: 'We are substantially dependent on the success of our most advanced product candidate, NGN-401, and our ongoing clinical trial of NGN-401 may not be successful.' (moved earlier in list in newer filing)
- Added more detailed CVR Agreement description in Summary: 'dated December 18, 2023, by and between us and the Rights Agent (the "CVR Agreement")' in newer filing vs. older filing which only referenced 'the CVR Agreement'
- Removed:
- Removed phrase 'or our current or future collaborators' from fourth bullet point in Summary - older filing stated 'If we or our current or future collaborators are unable to complete development' while newer filing states 'If we are unable to complete development'
- Reworded:
- In Summary bullets, reordered risk factors: older filing lists NGN-401 clinical development as fourth bullet and NGN-401 dependency as fifth bullet; newer filing reverses this order (dependency is fourth, clinical development is fifth)
- In detailed risk section, changed 'and have initiated dosing in our Embolden TM registrational trial for NGN-401 and have completed enrollment' to 'initiated dosing in our Embolden TM registrational trial for NGN-401 and completed enrollment' - removed 'and have' before 'initiated' and 'and have' before 'completed'
- In final incomplete sentence, older filing ends with 'larger pivotal clinic' while newer filing text appears truncated at same point, but older version context references 'early research and development focus' while newer references 'limited focus on early research and deve' (both incomplete)
- Notes:
- Both text excerpts end mid-sentence/incomplete, limiting full comparison of the detailed risk section
- Page number changes from -39- (older) to -35- (newer) suggest different document formatting but same content structure
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 5 sells ($339962) — 1 selling insider
- Last 180 days0 buys · 10 sells ($787444) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-07. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NGNE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NGNE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,157,353
- Reported value $43,492,236
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NGNE had 3,005,232 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NGNE had 15.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 16.15 days to cover at the same settlement.
- Reported short interest (shares) 3,005,232
- Short interest (% of shares outstanding) 15.0%
- Prior settlement (shares) 2,928,178
- Reported change 2.63%
- Days to cover (reported) 16.15
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Novartis (NVS)
- Roche (RHHBY)
- Sarepta Therapeutics (SRPT)
- PTC Therapeutics (PTCT)
- Takeda Pharmaceutical (TAK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NGNE vs…
Frequently asked questions
What does NEUROGENE INC (NGNE) do?
Neurogene is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. The company leverages its proprietary EXACT™ (Expression Attenuation via Construct Tuning) transgene regulation technology, which uses microRNA-based genetic circuits to deliver therapeutic levels of transgene to key brain areas.
What sector is NEUROGENE INC (NGNE) in?
NEUROGENE INC (NGNE) is classified in the Health Care sector. Its industry is Gene therapy / genetic medicines for neurological diseases. It trades on NASDAQ.
Who are NEUROGENE INC's (NGNE) competitors?
Notable peers of NEUROGENE INC (NGNE) include Biogen, Novartis, Roche, Sarepta Therapeutics and PTC Therapeutics. This peer set is informational only — not financial advice.
Is NEUROGENE INC (NGNE) overbought or oversold right now?
NEUROGENE INC (NGNE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NGNE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.